Prelude therapeutics reports first quarter 2024 financial results and provides corporate update

First-in-class iv smarca2 degrader, prt3789 and potentially best-in-class cdk9 inhibitor, prt2527 remain on track to generate initial proof-of-concept data in 2024
PRLD Ratings Summary
PRLD Quant Ranking